RxDoctor Payments Data

Romeo David, MD

Family Medicine · South San Francisco, CANPI 1164463386

Payments from drug & device makers

$2,987in general payments, 2019–2025

Across 72 payments — averaging $41.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novo Nordisk$209
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
  • Novartis$157
  • E.r. Squibb & Sons, L.L.C.$138
  • Actelion Pharmaceuticals US, Inc.$125
  • plus $507 from 6 others

What the payments were for

  • Food & beverage$2,982100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,987 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$97,005
Medicare patients
87
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate81$95,317
EliquisApixaban43$54,510
TrulicityDulaglutide19$32,396
JardianceEmpagliflozin17$21,886
XareltoRivaroxaban11$13,271
Albuterol Sulfate HfaAlbuterol Sulfate171$11,252
Advair HfaFluticasone Propion/Salmeterol19$7,950
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$7,259
Atorvastatin Calcium371$6,395
Atrovent HfaIpratropium Bromide13$6,241
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,727
Wixela InhubFluticasone Propion/Salmeterol18$3,668
Omeprazole201$2,619
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,616
Metformin Hcl292$2,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$79$32,39619 claims
Boehringer IngelheimJardiance$105$21,88617 claims
Johnson & JohnsonXarelto$1,645$13,27111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in South San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →